Siniša Savić
@sinisauksav
Followers
661
Following
548
Media
13
Statuses
446
Professor of Clinical Immunology, University of Leeds, Chair of BSI-CIPN, Clinical director of Leeds NIHR BioResource centre, views my own
England, United Kingdom
Joined February 2016
RT @BSI_CIPN: 🚨 Registration is now open for the BSI-CIPN Conference 2025!. Join clinical immunology professionals in Liverpool this Decemb….
0
5
0
RT @BSI_CIPN: 🚨 Abstract submissions are OPEN for #BSICIPN25!. In 2023, we had 220+ participants and 56 abstracts. Join this vibrant clinic….
0
1
0
RT @RheumJnl: New systematic review by @sinisauksav et al. characterises the complete phenotypic spectrum of VEXAS syndrome. ➡️These findi….
0
31
0
RT @TheLancetRheum: NEW podcast episode🎧 . Deputy Editor, Sophie Woolven, talks to @sinisauksav about treatment outcomes in #VEXAS syn….
0
4
0
It was pleasure to record a podcast about our recent paper on VEXAS treatment outcomes in the UK. If you interested to hear more please follow the link: In conversation with. Sinisa Savic
0
2
13
Please to share our comprehensive review of Clinical Features in VEXAS syndrome: a systematic review
academic.oup.com
AbstractObjective. To systematically characterize the complete phenotypic spectrum of VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) synd
5
22
51
RT @Sim_Orizon: 🔥 POS1124 | A major step for #VEXAS: an international expert panel reached consensus on the definition of a VEXAS flare usi….
0
6
0
Our contribution towards improved understanding of epidemiology of #VEXAS syndrome. British Journal of Haematology | Wiley Online Library
onlinelibrary.wiley.com
VEXAS syndrome is a late-onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK...
1
4
19
UK contribution towards improving treatment choices for VEXAS syndrome. We urgently need prospective RCTs! Treatment outcomes in patients with VEXAS syndrome: a retrospective co.
0
6
13
RT @casanova_lab: 1/ 2025 Kunkel Memorial Lecturer, Eric Vivier of @InnatePharma, kicked off the 2nd day of the 32nd annual Henry Kunkel So….
0
6
0
RT @FMFandAID: FMF & AID is pleased to announce the publication of our first magazine of 2025 highlighting our participation in ImmunAID, T….
0
4
0
RT @RheumatologyUK: 📢 Join us for our upcoming VEXAS webinar with Dr Sinisa Savic.🗓️7 May - 15:30-17:00.📚 CPD: 1 hour.Focus on VEXAS, cover….
0
4
0
RT @BogunovicLab: Thank you for the spotlight. 🙏🏼.Monoallelic expression in human immune cells: linking genotype to phenotype: Trends in Im….
cell.com
Patients with an inborn error of immunity (IEI) often show a complete penetrance of their disease-causing mutation, whereas other forms of IEI show a family pattern where many family members carrying...
0
10
0
RT @BSI_CIPN: ℹ️ Availability of different immunoglobulin products is changing from 1 April . We have produced a short guidance document t….
0
4
0
RT @SaraBindoli: VEXAS for lunch!!🫁👁👂🩸🧬.With @SophieGeorgin and @sinisauksav .Don't miss it!! .When👉 next tuesday, February 4th, 2025.
0
1
0
RT @LeedsBRC: Thrilled our research on #Methotrexate for knee pain made @RheumNow & @Medscape 'Best of 2024' lists!. Links to mentions 👇 .R….
0
5
0
Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective A comprehensive review thanks to hard work and enthusiasm from @allergy_catcher.
pubmed.ncbi.nlm.nih.gov
B-cell depleting therapy (BCDT) has revolutionised the treatment of B-cell malignancies and autoimmune diseases by targeting specific B-cell surface antigens, receptors, ligands, and signalling...
0
5
8
RT @AAlliance_SAID: Abstracts due Dec 18th! Register for the International Society of Systemic #Autoinflammatory Diseases (ISSAID) Congress….
0
9
0
RT @britsocimm: The @BSI_CIPN improves patient outcomes by equipping the #immunology community to tackle future challenges 🛡️. September’s….
0
2
0